New Haven, Connecticut, United States
My professional mission is to leverage my expertise and passion for advancing cancer care and research to improve the lives of patients and their families in local communities and around the world. I recently joined the Yale Cancer Center as Professor and Director, Precision Medicine and Senior Advisor to the YCC Director. I am also Service Line Medical Director at Smilow Cancer Hospital at Greenwich, leading a strategic approach to cancer program building. As a board-certified medical oncologist with >25 years of clinical and translational research experience, I held previous leadership roles at Harvard and Mount Sinai, developing innovative clinical trials and clinicogenomic databases to build novel approaches to treating cancer. As Chief Medical Officer at the publicly-traded health intelligence company, Sema4, I drove adoption of precision medicine integrating genomics and clinical data. As the inaugural CMO for the Prostate Cancer Foundation, I led efforts to reduce mortality by focusing on implementation efforts in screening for Black men in the US as well as delivering combination therapy to patients with metastatic hormone-sensitive disease.
I am focused on building a cohesive program in precision cancer medicine, integrating basic and translational science, clinical trials, and Smilow Cancer Hospital’s Precision Medicine Tumor Board. Increasing the routine use of molecular and genetic testing for all patients with cancer will improve patient outcomes.
Delivering outstanding multidisciplinary care for prostate cancer patients has been a priority for my whole career. I have been consecutively honored as a Top Doctor by Castle Connolly, New York Magazine and most recently, Connecticut Magazine. I will continue my teaching and research as well.
In this role, I will continue to grow outstanding integrated oncology care teams and expand the impact of multidisciplinary cancer care for patients in the region.
Previvor Edge is an innovative startup focused on a technology-enabled clinical program for assessing and addressing cancer risk by early detection and prevention.
NTx Bio has developed benchtop platforms for creating personalized RNA vaccines that will help cancer investigators and patients. I am helping them to collaborate with top academic centers to accelerate this technology to improve patient outcomes.
As Chair of the SAB, I am helping Archetype use their novel AI-generated modeling platform to screen billions of drugs to predict the best drugs for unmet medical needs like prostate and lung cancer.